

Evaluation of Oxidative Stress Status in Testosterone and Estradiol Induced Benign Prostatic Hyperplasia in Wistar Rats

Abstract

Background: The greatest risk factor for developing benign prostatic hyperplasia (BPH) is advanced age. As BPH and aberrant changes in reactive oxygen species become more common with aging, oxygen species signaling may play an important role in the development and progression of this disease. In this study, we investigated the effect of Nigerian indigenous plant; *Vernonia amygdalina* (VA) on oxidative stress indices in BPH induced rats.

Method: BPH was induced in male rats weighing 200-300g through exogenous administration of testosterone and estradiol by subcutaneous injection at a dose of 400µg T and 80µg E₂ respectively. Thirty (30) rats were divided into five groups. One group was used as a normal control and the other groups received subcutaneous injections of the hormones for 3 weeks to induce BPH. Groups I and II were treated with different doses of VA extract and group III received finasteride, all by gavages for forty-two days, while group IV was left untreated, group V served as normal control. After forty-two days of treatment with VA extract, the rats were anaesthetised by short contact with trichloromethane vapour. Blood was collected by cardiac puncture and the sera centrifuged and used for the determination of different biochemical indices. The liver and kidney were harvested and homogenized and used for the assays of oxidative activities.

Results: The activities of CAT and SOD in the extract treated rats were significantly increased when compared the BPH control which had a significant reduction in the activities of these enzymes. The concentration of GSH in the extract treated group significantly

($P<0.05$) increased while TBARS concentration decreased when compared to BPH control group.


Conclusion: Human prostate tissue is vulnerable to oxidative damage due to more rapid cell turnover. Therefore *Vernonia amygdalina* can be used to reduce lipid peroxidation as a result of oxidative damage from BPH.

Keywords: Oxidative stress, Prostate, *Vernonia amygdalina*, finasteride, Wistar Rats

1. Introduction

Potential molecular and physiologic contributors to the frequency of BPH occurrence in older individuals include the oxidative stress, chronic inflammation, and alterations in tissue microenvironment. Increased oxidative stress is a result of either increased reactive oxygen species generation or a loss of antioxidant defense mechanisms. Oxidative stress is associated with several pathological conditions including inflammation and infection [1]. Oxygen species are byproducts of normal cellular metabolism and play vital roles in stimulation of signaling pathways in response to changing intra and extracellular environmental conditions.


Several parameters including inflammatory mediators, hormones, dietary factors, inflammatory genes, and oxidative stress (OS) have been considered to play a role in the development of BPH, but there is no consensus as to which is the primary one [2, 3]. To date, these multifactorial and chronic conditions have been studied to prevent BPH progression. In the last few years, a relationship between prostatic inflammation and lower urinary tract symptoms related to BPH has been suggested [4]. Today, even though it is not yet known exactly when and why chronic inflammation occurs, it has been hypothesized that BPH is an immune-mediated inflammatory disease and inflammation may directly contribute to prostate growth [4].

48 Medicinal plants have formed the basis of health care throughout the world since the
49 earliest days of humanity and have remained relevant in both developing and the developed
50 nations of the world for various chemotherapeutic purposes. Plants have ability to synthesize
51 a wide variety of chemical compounds such as resins, alkaloids, glycoside, saponins, lactose
52 and essential oils [5]. Many of these phytochemicals have beneficial effects on a long term
53 human health and may be used to effectively treat human disease [6, 7]. 

54 Antioxidants are substance or molecules that are capable of neutralizing the harmful
55 effects of the reactive oxygen species (ROS) through the endogenous enzymatic defense
56 system. The antioxidant effect of plant is mainly due to phenolic components like flavonoids,
57 phenolic acids and phenolic diterpenes [8]. The antioxidants capacity of phenolic compounds
58 is mainly due to their redox properties, which play an important role in absorbing and
59 neutralizing free radicals, quenching singlet and triplet oxygen and decomposing peroxides
60 [9].

61 **2.0. Materials and Methods**

62 **2.1. Plant Material**

63 Fresh leaves of *Vernonia amygdalina* was harvested from a garden in Okuku in Yala
64 Local Government of Cross River State, South-South, Nigeria. The plant was identified at the
65 herbarium  of the Department of Biological Sciences, University of Calabar. Their fresh
66 leaves were washed with clean water and dried under the shade for six days. Their dried
67 leaves were milled using pestle and mortar to get a powder that was used for extraction.

68 **2.1.1 Preparation of extract**


69 The powdered sample of *Vernonia amygdalina* 200g was soaked into 200ml of distilled
70 water, this was filtered after 48 hours and filtrate was concentrated in water bath. The

71 solutions were diluted with corn oil, to produce a solution 100mg/ml. The administration of
72 extract was totally by gavage.

73 2.2. Hormones

74 Testosterone propionate Brand name: Ricostrone; a product of Greenfield pharma,
75 Jiangsu Co Ltd., China. Estradiol valerate (by Medipharma Ltd., 108-Kotlakhpat industrial
76 Est; Lahore, India. Testosterone propionate (T) and estradiol valerate E₂ (puregynon depot)
77 were used for the induction of prostate enlargement at a dose of 400µg and 80µg E₂ [10].
78 This was administered to the rats for three weeks subcutaneously in the inguinal region after
79 which a few rats were sacrificed and inspected for gross examination of prostate enlargement.
80 All Chemicals used in this study were of analytical grade and were obtained from reputable
81 companies.


82 2.3. Animals

83 A total of thirty (30) Wistar rats weighing between 200-300g were obtained from the
84 animal house of the Faculty of Basic Medical Sciences, Cross River University of
85 Technology, Okuku Campus, Nigeria. The rats were used for the experiment. The rats were
86 acclimatized for two weeks before the experiment commences. The rats were exposed to
87 approximately 12-hour light/dark cycles under humid tropical conditions, given tap water and
88 feed *ad libitum*, and were housed in standard plastic cages (five per cage) throughout the 42-
89 day duration of the study. The animal room was well be ventilated with a temperature range
90 of 27-29 °C. The Institutional Animal Ethics Committee approved the study before the
91 experiment and certified all experimental protocols. 

92

93


94 2.3.1. Induction of BPH

95 BPH was induced by exogenous administration of testosterone and estradiol in
96 staggered doses (three times a week respectively) for three weeks according to [10] with
97 modification by [11]. 

98 2.3.2. Animal grouping and treatment

99 The animals were divided into five (5) groups each comprised of six (6) male rats.
100 Four groups were induced with BPH which were grouped as group I to group IV). Groups I
101 and II received 50 and 100mg kg⁻¹ body weight (bw) of *Vernonia amygdalina* extract; group
102 III received finasteride (orthodox drug) at 0.1mg kg⁻¹; all by gavages for forty two days,
103 group IV was left untreated for forty two days before sacrifice to assess possible reversal of
104 the exogenous induction and group V served as normal control. The animals were weighed
105 prior to the commencement of the experiment and subsequently every week till the end of the
106 experiment.

107 2.4. Determinations of Biochemical Parameters

108 After 42 days, the rats were anaesthetized by a brief exposure to trichloromethane
109 vapour and bled by cardiac puncture. Blood samples were collected and transferred into
110 vacutainers without anticoagulant, and serum was separated by centrifugation at 2,500 rpm 
111 for 15 min using bench top centrifuge (MSE Minor, England). After centrifugation serum
112 samples were collected using dry Pasteur pipette and stored in the in a freezer at -20°C until
113 use. All analyses were completed within 24 h of sample collection. The liver and kidney were
114 harvested and homogenized and used for the assays of oxidative activities.

115 2.4.1. Determination of thiobarbituric acid reactive substance (TBARS) concentration

116 Thiobarbituric acid reactive substance (TBARS) in tissues was determined by the
 117 procedure of [12]. At low pH 3.5 and high temperature (100°C) Malondialdehyde (MDA)
 118 binds with thiobarbituric acid (TBA) to produce a pink colour that can be measured at
 119 532nm.

120 **2.4.2. Assay for catalase activity**

121 Catalase was assayed according to the method of [13]. Catalase can act on H₂O₂ to
 122 yield H₂O and O₂. The concentration of H₂O₂ in the in absorbance reading after 10min was
 123 determined as catalase activity expressed in terms of units/mg protein. The absorbance was
 124 measured at 230nm.

125 **2.4.3. Determination of superoxide dismutase (SOD) activity**

126 Superoxide Dismutase activity assay was carried out according to the method
 127 described by [14]. Exactly 920µL of assay buffer (Phosphate buffer pH 7.8) of 0.05M was
 128 added into clean test tube containing 40µL of sample; they were mixed and incubated for
 129 2mins at 25°C. 40µL of hematoxylin solution was added, mixed quickly and the absorbance
 130 was measured at 560nm. Auto-oxidation of hematoxylin is inhibited by SOD at the assay pH,
 131 the percentage of inhibition is linearly proportional to the amount of SOD present within a
 132 specific range [14].

133 **2.4.4. Estimation of glutathione concentration**

134 The method of [15] was followed in estimating the level of reduced glutathione
 135 (GSH). The reduced form of glutathione comprises in most instances the bulk of cellular non-
 136 protein sulfhydryl groups. This method is therefore based upon the development of a
 137 relatively stable yellow colour when 5, 5 – dithiobis – (2-nitrobenzoic acid) (Ellman's

reagent) is added to sulfhydryl compounds. The chromophoric product resulting from the reaction of Ellaman's reagent with the reduced glutathione, 2- nitro-5-thiobenzoic acid possesses a molar absorption at 412nm. Reduced GSH is proportional to the absorbance at 412nm.

2.5. Statistical Analysis

The experimental data were analysed for statistical significance by one-way analysis of variance and post hoc comparison using the SPSS version. The Independent Samples t test was used to compare the means of two independent groups. All data were reported as mean \pm SD and statistical significance was accepted at $P < 0.05$.

3.0. Results

3.1. Liver and Kidney Superoxide Dismutase (SOD) Activity

There was a significant ($P < 0.05$) decrease in activity of superoxide dismutase in the liver and kidney of the BPH control group when compared with the normal control. Treatments with extract and standard drug exhibited a significant increase in the activity of superoxide dismutase when compared with the BPH control.

3.2. Concentration of Gluathione (GSH)

There was a significant reduction in the concentration of gluathione in the BPH control compared to normal control ($P < 0.05$). Administration of extract and standard drug showed a significant ($P < 0.05$) increase in the concentration of glutathione when compared to the BPH control group.

3.3. Liver and Kidney Catalase (CAT) Activity

The activity of catalase decreased significantly ($P < 0.05$) in the liver and kidney of BPH control group when compared with normal control. Administration of the extract and the standard drug significantly increased the catalase activity in the liver and kidney of treated groups when compared to the BPH control group.

3.4. Concentration of Liver and Kidney Malondialdehyde (MDA)

There was a significant ($P < 0.05$) increase in malondialdehyde (MDA) in the liver and kidney of BPH control group when compared with the normal control. Treatment with the extract and the standard drug significantly ($P < 0.05$) decreased the MDA concentration in the liver and kidney of treated groups.

Table 1: Effect of aqueous extracts of *Vernonia amygdalina* (VA) in BPH induced Wistar rats on Catalase and MDA of Liver.

GROUP	SOD LIVER (mg Protein)	CAT LIVER (mg Protein)	MDA LIVER (mg Protein)	GSH (mg/g)
BPH + 50mg VA	9.70±0.90 ^{bc}	65.66±1.87 ^b	30.12±0.89 ^{ab}	65.87±1.71 ^{bc}
BPH + 100mg VA	10.84±1.46 ^d	73.75±3.27 ^{cd}	29.91±1.89 ^{ab}	68.48±4.39 ^c
BPH + FINASTERIDE	9.14±0.77 ^{bc}	68.55±1.91 ^{bc}	30.71±0.58 ^{ab}	65.71±2.97 ^{bc}
BPH CONTROL	4.24±0.86 ^a	31.62±4.98 ^a	42.41±1.41 ^c	37.86±1.61 ^a
NORMAL CONTROL	12.30±1.20 ^e	79.52±10.54 ^d	27.58±4.45 ^a	73.91±0.76 ^d

Values are expressed as Mean ± SD. Benign prostate hyperplasia (BPH) *Vernonia amygdalina* (VA). Identical superscript (i.e. a) means there is no significant difference between the comparing group $P > 0.05$. Non- identical superscripts (i.e. a, b, c, d, e) means there is significance between the comparing groups at $P < 0.05$.

Table 2: Effect of aqueous extracts of *Vernonia amygdalina* (VA) in BPH induced Wistar rats on Catalase and MDA of Kidney.

Group	SOD Kidney (mg Protein)	CAT Kidney (mg Protein)	MDA Kidney (mg Protein)
BPH + 50mg VA	8.75±0.66 ^{bc}	72.99±4.67 ^{bc}	36.51±2.55 ^{bc}
BPH + 100mg VA	9.65±0.95 ^c	75.98±4.29 ^{cd}	35.70±2.62 ^{ab}
BPH + Finasteride	8.95±1.44 ^{bc}	76.50±7.69 ^{cd}	36.31±2.26 ^{bc}
BPH Control	4.67±0.83 ^a	38.37±3.58 ^a	44.49±4.36 ^d
Normal Control	11.31±0.83 ^d	80.83±7.58 ^d	34.54±3.56 ^a

Values are expressed as Mean ± SD. Benign prostate hyperplasia (BPH) *Vernonia amygdalina* (VA). Identical superscript (i.e. a) means there is no significant difference between the comparing group $P > 0.05$. Non- identical superscripts (i.e. a, b, c, d) means there is significance between the comparing groups at $P < 0.05$.

4. Discussion

Lipid peroxidation is a well-established mechanism of cellular injury in both plants and animals. This process, leading to the production of lipid peroxides and their byproducts, and ultimately to the loss of membrane function and integrity, is widely accepted to be involved in the pathogenesis of several human diseases [16, 17]. Several studies demonstrated the presence of oxidative stress (OS) in BPH [3]. The cause of enhanced oxidative stress could be the overproduction of free radicals or decrease in the activities of free radical scavenging enzymes like SOD, GST, GR and glutathione levels in their circulation, or both [3, 4, 18].

Humans are naturally protected against free radical damage by oxidative enzymes and proteins such as Superoxide Dismutase (SOD), Catalase (CAT) and glutathione as well as

196 phytochemicals. Many plants have been identified as good sources of natural antioxidants
197 which protect against degenerative diseases and cancer [19, 20]. In this present study the
198 administration of extract to the animals increased the activity of these endogenous antioxidant
199 enzymes compared to the BPH control. The extract might have reactivated the activities of
200 these enzymes through its active compounds that enhanced the scavenging effect of the
201 enzymes against reactive oxygen species (ROS) thereby reducing its oxidative damages [7].
202 Some studies have justified the antioxidant mechanism of *Vernonia amygdalina* [21, 22]. The
203 antioxidant activity of *Vernonia amygdalina* has been attributed to the presence of
204 flavonoids, as reported by [23]

205 Free radicals cause attack on polyunsaturated membrane lipid (lipid peroxidation)
206 generating a product called malondialdehyde (MDA) [24]. MDA is an end-product derived
207 from peroxidation of polyunsaturated fatty acids and related esters. In contrast to free
208 radicals, aldehydes are relatively stable and therefore able to diffuse within or out of the cell
209 and to attack targets distant from the site of original free-radical-initiated events. In this study
210 there was a significantly higher level of MDA in BPH control groups when compared with
211 extract treated and normal control. Administration of the extract to the rats caused a
212 significant reduction in the level of MDA compared to BPH control group. Some previous
213 studies revealed similar trend [2, 25, 26].

214 The increase in the oxidative capability seen as improved activities of SOD, CAT and
215 rise in level of GSH and decrease in level of MDA of the rats treated with *Vernonia*
216 *amygdalina* could provide a promising substitute revealing the protective effects of the plant
217 against BPH [27, 28]. The antioxidant compounds in *Vernonia amygdalina* might have
218 caused this protective effect against BPH.

219 **5. Conclusion**

The study showed that *Vernonia amygdalina* exhibited antioxidant properties and proved to have the capacity to prevent or delay the development and progression of BPH. It therefore means that consumption of *V amygdalina* leaves appear to have some protective effect on a prostate hyperplasia. Hence a promising research for scientists to explore and find out its mechanism of action. This will also act as a remedy for other prostate related diseases including prostate cancer.

References

1. Savas M. Oxidative Stress in Benign Prostate Hyperplasia. In: Agarwal A, Aitken R, Alvarez J. (eds) Studies on Men's Health and Fertility. Oxidative Stress in Applied Basic Research and Clinical Practice. *Humana Press*, 2012; pp 591-615.
2. Ugwu MN, Asuk AA, Utu-Baku A.B, Eteng MU. Tissue-Protective effect of *Prosopis africana* seed extract on testosterone and estradiol induced benign prostatic hyperplasia of adult male rats. *International Journal of Innovative Research and Advanced Studies*, 2018b; 5 (3): 72-77.
3. Minciullo PL, Infrerra A, Navarra M, Calapai G, Magno C, Gangemi S. Oxidative Stress in Benign Prostatic Hyperplasia: A Systematic Review, *Urol Int*; 2015; 94:249–254
4. Bostanci Y, Kazzazi A, Momtahn S, Laze J, Djavan B. Correlation between benign prostatic hyperplasia and inflammation. *Curr Opin Urol*; 2013; 23: 5–10.
5. Kwee EM, Niemeyer ED. Variations in phenolic composition and antioxidant properties among 15 basil (*Ocimum basilicum* L.) cultivars. *Food Chem*. 2011, 128 (4): 1044-1050.
6. Lai PK, Roy J. Antimicrobial and chemopreventive properties of herbs and spices. *Journal of Current Medicinal Chemistry*, 2004; 11(11): 1451-60.
7. Ugwu MN, Ogueche PN, Eteng MU, Eno MA. Protective Effects of Aqueous Extract of *Ocimum gratissimum* on Prostate Functions in Hormonal Induced Enlarged Prostate in Adult Rats. *Asian Journal of Research in Biochemistry*, 2018a; 2(2): 1-12.
8. Shahidi F, Janitha PK, Wanasundara PD. Phenolic antioxidants. *Critical Rev. Food Sci. Nutr.*, 1992; 32(1): 67 103.

9. Osawa T. Novel natural antioxidants for utilization in food and biological systems. In I. Uritani VV, Garcia EM, Mendoza (Eds.), *Postharvest Biochemistry of Plant Food-Materials in the Tropics*. Tokyo, Japan: *Japan Scientific Societies Press.*, 1994; 241-251.
10. Bernoulli J. *An Experimental Model of Prostatic Inflammation for Drug Discovery*. Finland: University of Turku, 2008;139 p.
11. Mbaka G, Anunobi C, Ogunsina S, Osiagwu D. Histomorphological changes in induced benign prostatic hyperplasia with exogenous testosterone and estradiol in adult male rats treated with aqueous ethanol extract of *Secamone afzelii*, *Egyptian Journal of Basic and Applied Sciences*, 2017; 4:15–21.
12. Fraga CG, Leibovitz BE, Toppel AL. Lipid peroxidation measured as TBARS in tissue slices: Characterization and comparison with homogenates and microsomes. *Free radical and Biological Medicine*, 1988; 4: 155-161.
13. Machly AC, Chance B. (Methods of Biochemical analysis, Vol 1, Glick D (ed.) *Interscience*: New York, 1954; 357.
14. Martin JP, Dailey M, Sugarman E. Negative and positive assays of superoxide dismutase based on heamatoxylin autoxidation. *Archive of Biochemistry and Biophysics*, 1987; 255: 329-336.
15. Rukkumani R, Aruna K, Varma PS, Rajasekaran KN, Menon VP. Comparative effects of *curcumin* and analog of *curcumin* on alcohol and PUFA induced oxidative stress. *Journal of Pharmaceutical Sciences*, 2004; vol. 7, n. 2, p. 274-283.
16. Meagher EA, FitzGerald GA. Indices of lipid peroxidation in vivo: strengths and limitation. *Free Radic Biol Med*, 2000; 28: 1745-1750.
17. Muradian K, Schachtschabel DO. The role of apoptosis in aging and age-related disease: update. *Z Gerontol Geriatr*, 2001; 34: 441-446.
18. Ahmad M, Suhail N, Mansoor T, Banu N, Ahmad S: Evaluation of oxidative stress and DNA damage in benign prostatic hyperplasia patients and comparison with controls. *Indian J Clin Biochem*, 2012; 27: 385–388.
19. Javanmardi J, Stushnoff C, Locke E, Vivano JM. Antioxidant activity and total phenolic content of Iranian *Ocimum* accessions. *Food Chem.*, 2003; 83: 547-550.
20. Arabshahi S, Devi DV, Urooj A. Evaluation of antioxidant activity of some plant extracts and their heat, pH and storage stability. *Food Chem.*, 2007; 100: 1100-1105.

- 282 21. Farombi EO, Owoeye O. Antioxidative and Chemopreventive Properties of *Vernonia*
283 *amygdalina* and *Garcinia biflavonoid*. *Int. J. Environ. Res. Public Health*, 2011; 8,
284 2533-2555.
- 285 22. Adesanoye OA. Farombi EO. Hepatoprotective effects of *Vernonia amygdalina*
286 (astereaceae) in rats treated with carbon tetrachloride. *Exp. Toxicol. Pathol.* 2010; 62,
287 197-206.
- 288 23. Igile GO, Oleszek W, Jurzysta M, Burda S, Fafunso M, Fasanmade AA. Flavonoids
289 from *Vernonia amygdalina* and their antioxidant activities. *J. Agric. Food Chem.*
290 1994, 42, 2445-2448.
- 291 24. Ugwu MN, Umar IA, Utu-Baku AB, Dasofunjo K, Ukpanukpong RU, Yakubu OE,
292 Okafor AI. Antioxidant Status and Organ Function in Streptozocin-Induced Diabetic
293 Rats treated with Aqueous, Methanolic and Petroleum Ether Extracts of *Ocimum*
294 *basilicum* Leaf in. *Journal of Applied Pharmaceutical Science*, 2013; 3 (5): S75-S79.
- 295 25. Mittal R, Scrivastava D. Free radical injury and antioxidant status in patients with
296 BPH and prostate cancer. *Indian Journal of Clinical Biochemistry*, 2005; 20(2): 162-
297 165.
- 298 26. Savas MA, Verit H, Ciftci E, Yeni Y, Aktan E. Oxidative Stress in BPH. *Journal of*
299 *Nepal Medical Association*, 2009; 48(173): 41-45.
- 300 27. Zhang K, Mack P, Wong KP. Glutathione-related mechanisms in cellular resistance to
301 anticancer drugs. *Int. J. Oncol.*, 1998; 12: 871-882.
- 302 28. Iweala EEJ, Ogidigo JO. Prostate Specific Antigen, Antioxidant and Hematological
303 Parameters in Prostatic Rats Fed *Solanum macrocarpon* L. Leaves. *Asian Journal of*
304 *Biological Sciences*, 2015; 8 (1): 30-41.